LNS Research Principal Analyst, Dan Jacob, answers the 5 most asked questions from the Quality 4.0 webcast held on Thursday, August 24 2017.
In mid-2017, LNS Research identified that an early but significant group of manufacturers had begun to recognize Quality 4.0 as one of their top Industrial Transformation initiatives. LNS coined the term Quality 4.0 and defined the space - why to adopt Quality 4.0, and how to build a successful strategy. Over time, the interest in Quality 4.0 has continued to accelerate, and many manufacturers are now either investigating Quality 4.0 or deploying early pilots
Pharmaceutical firms have been one of the early adopters of Quality 4.0 and have already deployed Quality 4.0 use cases across product development, clinical trials, laboratories, manufacturing operations, logistics, and pharmacovigilance. Many are pivoting to explore opportunities presented by the FDA’s increasing openness to real-world data while finding solutions that improve the ability to navigate global compliance complexity.
Learn from Early Mistakes
Quality 4.0 innovators experienced successes and setbacks in their journeys. Many in the broad market have been trapped in what is being called “pilot purgatory,” where initial Industrial Transformation pilots do not either deliver value or scale.
Several root causes are prevalent in these early failures:
Shiny Object Syndrome (SOS):
One prevalent idea is that firms can deploy new tech in many separate pilots without clearly defined business value. Business value is not an incidental byproduct; start with strategic/peer objectives and tightly define use cases.
Tech vs. Transformation:
While technology is the enabler, it is not the end goal. Those that do not transform their cultures, products, and processes spend substantial financial and time outlay to achieve marginal results (or churn). LNS’ core Quality 4.0 research highlights the importance to transform across 11 axes.
New Digital Silos:
Many firms have independent initiatives that have sprung up at various sites and across multiple parts of the value chain, in support of the “fail fast” mantra. These initiatives do not build upon each other and are creating new digital silos to replace traditional silos. By contrast, successful firms have typically taken a centralized, flexible approach that ultimately integrates and scales transformation.
Lack of Top Management Support:
As with most transformations, a bottom-up or mid-out transformation is much slower and less effective than one that can rely on top management to softly or firmly encourage adoption. LNS’ quality maturity research identifies that quality teams with top management priority have 2.9 times more people, process, and tech capabilities than those without. This helps quantify top management’s impact on success.
Larger firms are aware that some sites have a much greater appetite and an ability for change than others. Also, in some firms, the power may rest with large sites or business units rather than corporate. While LNS is exploring this in more detail in forthcoming research, the advice, for now, is to be careful to identify the sites that are most ready and willing to transform and use these sites as beacons of success.
Poor Solution Selection:
Solution selection is where many of the above bad behaviors are embodied. It also is where teams often waste precious months or years investigating solutions without realizing that they are squandering time to value.
LNS is excited to launch the concept of “use case plots.” Use case plots are built to address many of the challenges outlined in this blog. They make it is possible to map the capabilities deployed in the operational theatre and in the enterprise software theatre, with analytics and insights.
The use case plots are then used to map a journey from the current state to a transformative future state. For instance, pharmaceutical firms can leverage use case plots to grow from a low-capability environment to individually connected manufacturing assets to predictive product quality, then from predictive product quality to predictive patient experiences.
Pharmaceutical firms are increasingly adopting technology to drive Quality 4.0. Firms are investigating this journey, and those currently underway should get educated on how others have succeeded and failed on their road to Quality 4.0.
All entries in this Industrial Transformation blog represent the opinions of the authors based on their industry experience and their view of the information collected using the methods described in our Research Integrity. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.